Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Clinical trial NCT03572634 · TERMINATED
Trial details
- NCT number
- NCT03572634
- Sponsor
- Sumitomo Pharma America, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-10
- Primary completion
- 2020-01-21
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.